ALNY · US market

ALNYLAM PHARMACEUTICALS

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$30.93bnFinancials dated 30 June 2026Price dated 1 October 2026

Core valuation

Trailing P/E39.93×
Latest-quarter run-rate P/E47.01×
Trailing P/S6.44×
Latest-quarter run-rate P/S5.99×

Calculation inputs

Trailing earnings
US$774.71m
Latest-quarter run-rate earnings
US$657.98m
Latest fiscal-year earnings
US$313.75m
Trailing revenue
US$4.80bn
Latest-quarter run-rate revenue
US$5.16bn
Latest fiscal-year revenue
US$3.71bn

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

  • IBBQ · Invesco Nasdaq Biotechnology ETF4.84% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
  • PBE · Invesco Biotechnology & Genome ETF4.84% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
  • BBH · VanEck Biotech ETF3.83% weight · Holdings dated 30 June 2026
  • NUMG · Nuveen ESG Mid-Cap Growth ETF3.23% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
  • FMED · Fidelity Disruptive Medicine ETF2.79% weight · Holdings dated 31 May 2026
  • TMED · T. Rowe Price Health Care ETF2.60% weight · Holdings dated 30 June 2026
  • NWZLX · Nationwide Loomis All Cap Growth Fund Class A2.57% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
  • FBT · First Trust NYSE Arca Biotechnology Index Fund2.52% weight · Holdings dated 30 June 2026
  • ATHAX · American Century Heritage Fund A Class2.38% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
  • IBB · iShares Biotechnology ETF2.21% weight · Holdings dated 19 August 2026

Sources and limitations

Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 30 June 2026. Informational research, not investment advice.